数千万融资！高压造影注射系统研发企业完成A轮

Core Viewpoint - Shenzhen Lenk Medical Technology Co., Ltd. has completed a multi-million RMB Series A financing round, led by Bangqin Capital, to enhance its high-pressure contrast injection technology and expand its product offerings and international market presence [2]. Market Size and Structure - The global market for high-pressure contrast injectors is projected to reach approximately $2.08 billion in 2024, with consumables accounting for about $1.6 billion and devices around $480 million, expecting a compound annual growth rate (CAGR) of approximately 10.9% from 2025 to 2030 [3]. - In China, the market for high-pressure contrast injectors reached 2.72 billion RMB in 2017, with consumables making up over 60% of the market share, driven by the rapid growth of enhanced CT and interventional imaging [5]. - As of 2023, the market for high-pressure contrast consumables in China has reached 3.97 billion RMB, reflecting a year-on-year growth of 8.4%, with a significant gap in per capita usage compared to the U.S. [6]. Company Overview - Shenzhen Lenk Medical was established in May 2024, focusing on high-pressure contrast and minimally invasive surgical fields, with over 60 intellectual property rights filed or granted [7]. - The company has developed a comprehensive product matrix for high-pressure contrast injectors, including the Nova UC3000 series, which features patented "precise dual-flow mixing" technology for enhanced clinical applications [10]. Team and Engineering Capability - The core team of Lenk Medical comprises members from Mindray Medical and the Chinese Academy of Sciences, possessing extensive experience in electromechanical systems and imaging-related equipment [11]. - Within less than a year, the company has achieved simultaneous progress in R&D, registration, and market expansion, with its devices already in use across multiple provinces and top-tier hospitals [11]. International Expansion - Lenk Medical's products are now available in over 20 countries and regions, with ongoing efforts to build overseas channels and brand recognition through participation in international medical exhibitions [12]. Conclusion - The high-pressure contrast system, while a niche segment within imaging equipment, presents long-term value potential for domestic alternatives due to its technical barriers and clinical integration [13]. The recent financing will support Lenk Medical's continued development in high-pressure contrast technology and its global expansion efforts [13].